Dr Zelenko’s HCQ-based ALT-ernative to the near-Business As Usual (n-BAU) approach
Jerry drew our attention last night to a radio interview by Dr Vladimir Zelenko. In this interview, he summarises his approach and rationale, giving results and making several announcements. (Unfortunately, the media cannot be embedded at UD as it is not YT. Kindly, go here; and make sure your browser has no active ad blocker.) On listening last night, here are my first observations on highlight points: Brazil and Israel are doing his early treatment, clinical diagnosis (backed up by nasal swab test), outpatient-oriented dosage for vulnerable patients protocol, ALT-1. He has treated 405 in that profile and sees 95% reduction on the expected death rate for the n-BAU baseline. He points out that the Raoult [by implication] protocol, which Read More ›